Alonzo A

Neurostimulation Centre, University of New South Wales, Australia.

3 papers

ArticleKetamine

Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.

Glozier N, Morris R, Stratton E +21

Europe PMC2026
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response.

Loo C, Alonzo A, Barton D +9

Europe PMC2025
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.

Loo C, Glozier N, Barton D +35

Europe PMC2023